Table 6.

Mixed-effect linear regression analysis for change from baseline in plasma p-tau181 according to intervention groups and plasma p-tau181 status among non-demented, community-dwelling older adults

	Estimated mean within-group change from baseline 1 (95% CI); P-value				Between-group difference over time (95% CI); P-value		Difference in betweengroup differences over time for high vs. low p-tau
	Nutritional blend		Placebo		Nutritional blend vs. placebo
	Low p-tau2	High p-tau3	Low p-tau2	High p-tau3	Low p-tau2	High p-tau3
Plasma p-tau181 (pg/ mL) (n=289)	0.77 (-0.41, 1.95); 0.202	3.22 (1.43, 5.02); 0.001	0.77 (-0.37, 1.92); 0.184	2.42 (0.63, 4.21); 0.008	0.00 (-1.48, 1.47); 0.995	0.81 (-1.27, 2.88); 0.446	0.81 (-1.74, 3.36); 0.532
Plasma GFAP (pg/ mL) (n=283)	12.57 (0.41, 24.74); 0.043	18.62 (1.38, 35.86); 0.034	11.68 (-0.28, 23.63); 0.056	30.21 (13.01, 47.42); 0.001	0.90 (-15.99, 17.78); 0.917	-11.59 (-35.58, 12.39); 0.342	-12.49 (-41.69, 16.72); 0.401

GFAP, glial fibrillary acidic protein; p-tau181, phosphorylated tau at threonine 181; 1Estimated with the mean at baseline; 2Defined as the two first tertiles (<15.1 pg/mL); 3Defined as the third tertile (≥15.1 pg/mL).